Allogeneic hematopoietic stem cell transplantation in patients with advanced indolent lymphoproliferative disorders

Allogeneic hematopoietic stem cell transplantation in patients with advanced indolent lymphoproliferative disorders

Hematology Transfusion and Cell Therapy, March 2016

27208567

Ana Marcela Rojas Fonseca-Hial, Katya Parisio, Jose Salvador Rodrigues Oliveira

The role of allogeneic hematopoietic stem cell transplantation for advanced indolent lymphoproliferative disorders remains to be established. This paper aims to describe the results of allogeneic hematopoietic stem cell transplantation in patients with advanced indolent lymphoproliferative disorders. This article reports on 29 adult patients submitted to allogeneic transplantations from 1997 to 2010. Most had follicular non-Hodgkin lymphoma (n=14) or chronic lymphocytic leukemia (n=12). The median age was 44 years (range: 24-53 years) and 65% of patients were male. Only 21% had had access to rituximab and 45% to fludarabine. All had advanced disease (stage IV) with partial response or stable disease. Most underwent myeloablative conditioning n=17-59%). In this scenario, refractory disease was observed in seven (24%) patients, the 100-day mortality rate was 17% (n=5) and relapse occurred in four patients (18%). The main cause of death throughout the follow up was refractory disease in six of the 12 patients who died. Moderate and severe chronic graft-versus-host disease was frequent; about 41% of 24 patients analyzed. The overall survival rates and disease free survival at 42 months were 56.7% and 45.4%, respectively. According to Kaplan-Meyer analysis, the median time from diagnosis to transplant predicted the overall survival; however age, gender and conditioning regimen did not predict the prognosis. It was impossible to reach other conclusions because of the small sample size in this study. The role of allogeneic transplantations should be re-evaluated in the era of targeted therapy.